京都大学大学院医学研究科 血液・腫瘍内科学

研究

ホーム ＞ 研究 ＞ 臨床研究グループ

臨床研究グループ

2021年の業績

  • Iwasaki M, Kanda J, Arai Y, Kondo T, Ishikawa T, Ueda Y, Imada K, Akasaka T, Yonezawa A, Yago K, Nohgawa M, Anzai N, Moriguchi T, Kitano T, Itoh M, Arima N, Takeoka T, Watanabe M, Hirata H, Asagoe K, Le A, Miyatsuka I, Miyanishi M, Takaori-Kondo A. Establishment of a Predictive Model for GvHD-free, Relapse-free Survival after Allogeneic HSCT using Ensemble Learning.Blood Adv. 2021 , in press.
  • Wada F, Kanda J, Yoshioka S, Ishikawa T, Akasaka T, Ueda　Y, Hirata H, Arai Y, Yago K, Anzai M, Watanabe M, Ikeda T, Yonezawa A, Imada K, Itoh M, Kitano T,Tsuji M, Hishizawa M, Moriguchi T, Nohgawa M, Arima N, Asagoe K, Kondo T, Takaori-Kondo A, and Kyoto Stem Cell Transplantation Group (KSCTG). Single cord blood transplantation versus HLA-haploidentical related donor transplantation using post-transplant cyclophosphamide in patients with hematological malignancies. Transplantation. 2021, in press.
  • Miyao K, Kuwatsuka Y, Murata M, Nagafuji K, Teshima T, Takeuchi Y, Shiratori S, Najima Y, Uchida N, Tanaka M, Sawa M, Ota S, Fukuda T, Ozawa Y, Kako S, Kawakita T, Ara T, Tanaka J, Kanda Y, Atsuta Y, Kanda J, Terakura S; GVHD Working Group and Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy. Anti-thymocyte globulin could potentially overcome an adverse effect of acute GVHD in matched-related PBSCT. Transplant Cell Ther. 2021, in Press.
  • Shimomura Y, Sobue T, Hirabayashi S, Kondo T, Mizuno S, Kanda J, Fujino T, Kataoka K, Uchida N, Eto T, Miyakoshi S, Tanaka M, Kawakita T, Yokoyama H, Doki N, Harada K, Wake A, Ota S, Takada S,Takahashi S, Kimura T, Onizuka M, Fukuda T, Atsuta Y, Yanada M. Comparing Cord Blood Transplantation and Matched Related Donor Transplantation in Non-remission Acute Myeloid Leukemia.Leukemia . 2021, in press.
  • Kawajiri A, Kawase T, Tanaka H, Fukuda T, Mukae J, Ozawa Y, Eto T, Uchida U, Mori T, Ashida T, Kondo T, Onizuka M, Ichinohe T, Atsuta Y, Morishima S, and Kanda J, on behalf of the HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation. Bone Marrow Transplant. 2021, in press.
  • Yanada M, Konuma T, Yamasaki S, Harada K, Iwasaki M, Kobayashi A, Nishijima A, Tanaka M, Uchida N, Nakamae H, Fukuda T, Onizuka M, Ozawa Y, Sawa M, Katayama Y, Yoshioka S, Kimura T, Ichinohe T, Atsuta Y, Kanda J, Yano S. Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. Transplant Cell Ther. 27: 1005.e1-1005.e8, 2021.
  • Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kanda J, Fukuda T, Atsuta Y, Aoki J. Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. Bone Marrow Transplant. 56: 3008-3015, 2021.
  • Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Miyazaki T, Aotsuka N, Gotoh M, Watanabe R, Shono K, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.Ann Hematol . 100: 2763-2771, 2021.
  • Kurosawa S, Kaito S, Uchida N, Fukuda T, Doki N, Mori T, Hasegawa Y, Takada S, Sakaida E, Tanaka M, Ikegame K, Kanda J, Atsuta Y, Kako S. Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study. Leuk Lymphoma. 62: 2514-2520, 2021.
  • Konuma T, Kanda J, Yamasaki S, Harada K, Shimomura Y, Terakura S, Mizuno S, Uchida N, Tanaka M, Doki N, Ozawa Y, Nakamae H, Sawa M, Matsuoka KI, Morishige S, Maruyama Y, Ikegame K, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yanada M. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. Transplant Cell Ther. 27: 334.e1-334.e11, 2021.
  • Yokoyama H, Kanda J, Kawahara Y, Uchida N, Tanaka M, Takahashi S, Onizuka M, Noguchi Y, Ozawa Y, Katsuoka Y, Ota S, Ohta T, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Nakasone H, Morishima S. Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation.Bone Marrow Transplant . 56: 1352-1363, 2021.
  • Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis. Eur J Haematol. 106: 555-562, 2021.
  • Takakuwa T, Ohta K, Nakatani E, Ito T, Kaneko H, Fuchida SI, Shimura Y, Yagi H, Shibayama H, Kanda J, Uchiyama H, Kosugi S, Tanaka H, Kawata E, Uoshima N, Ishikawa J, Shibano M, Karasuno T, Shindo M, Shimizu Y, Imada K, Kanakura Y, Kuroda J, Hino M, Nomura S, Takaori-Kondo A, Shimazaki C, Matsumura I. Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma. Hematol Oncol. 39: 349-357, 2021.
  • Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Miyazaki T, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S. Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. Transplant Cell Ther. 27: 70.e1-.e8, 2021.
  • Sakurai M, Mori T, Kato K, Kanaya M, Mizuno S, Shiratori S, Wakayama T, Uchida N, Kobayashi H, Kubo K, Amano I, Ohta T, Miyazaki Y, Kanda J, Fukuda T, Atsuta Y, Kondo E. Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 56(6): 1462-1466, 2021.
  • Murao M, Hamada R, Kondo T, Miyasaka J, Yoshida M, Yonezawa H, Arai Y, Kanda J, Nankaku M, Ikeguchi R, Takaori-Kondo A, and Matsuda S. Analysis of the factors associated with physical functioning domain of QLQ-C30 in allogeneic hematopoietic stem cell transplantation patients at discharge: A cross-sectional study.Support Care Cancer .29(12): 7569-7576, 2021.
  • Fujimoto A, Ishida F, Izutsu K, Yamasaki S, Chihara D, Suzumiya J, Mitsui T, Doki N, Sakai H, Kobayashi H, Kanda J, Fukuda T, Atsuta Y, Suzuki R. Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow Transplant. 56(2): 347-356, 2021.
  • Oka T, Hishizawa M, Yamashita K, Shiraki K, Takaori-Kondo A. Successful treatment with famciclovir for varicella zoster virus infection resistant to acyclovir. J Infect Chemother. 27(5): 755-758, 2021.
  • Matsuo H, Wakita T, Hiramatsu H, Ohmori K, Kodama K, Nakatani K, Kamikubo Y, Iwamoto S, Kondo T, Takaori-Kondo A, Takita J, Tomizawa D, Taga T, Adachi S. Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression. Br J Haematol. 192(1): e7-e11, 2021.
  • Onda Y, Kanda J, Hanaoka N, Watanabe M, Arai Y, Hishizawa M, Kondo T, Yamashita K, Nagao M, Fujimoto T, Takaori-Kondo A. Possible nosocomial transmission of virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 100(3): 753-761, 2021.
  • Jo T, Yoshihara S, Arai Y, Ikemoto J, Onomoto H, Sugiyama H, Yoshihara K, Matsui K, Niwa N, Nakagawa Y, Kitawaki T, Kanda J, Takaori-Kondo A, Nagao M. [Clinical experience of leukapheresis for CD19 CAR-T cell therapy].Rinsho Ketsueki. 62(3): 163-169, 2021.
  • Wada F, Kanda J, Watanabe M, Arai Y, Hishizawa M, Kondo T, Yamashita K, Takaori-Kondo A. Favorable Outcomes after Single Cord Blood Transplantation for Patients with High-Risk Hematologic Diseases: A Single-Institute Retrospective Analysis. Transplant Cell Ther. 27(6): 495.e1-495.e9, 2021.
  • Hamada R, Arai Y, Kondo T, Harada K, Murao M, Miyasaka J, Yoshida M, Yonezawa H, Nankaku M, Ouchi S, Kitakubo W, Wadayama T, Kanda J, Takaori-Kondo A, Ikeguchi R, Matsuda S. Higher exercise tolerance early after allogeneic hematopoietic stem cell transplantation is the predictive marker for higher probability of later social reintegration. Sci Rep. 11(1): 7190, 2021.
  • Yanada M, Konuma T, Mizuno S, Saburi M, Shinohara A, Tanaka M, Marumo A, Sawa N, Uchida N, Ozawa Y, Onizuka M, Yoshioka S, Nakamae H, Kondo T, Kimura T, Kanda J, Fukuda T, Atsuta Y, Nakasone H, and Yano S. Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. Bone Marrow Transplant. 56(2): 387-394, 2021.
  • Onda Y, Kanda J, Sakamoto S, Okada M, Anzai N, Umadome H, Tashima M, Haga H, Watanabe C, Hanaoka N, Fujimoto T, Takaori-Kondo A. Detection of adenovirus hepatitis and acute liver failure in allogeneic hematopoietic stem cell transplant patients. Transpl Infect Dis. 23(2): e13496, 2021.
  • Shimizu T, Kondo T, Nannya Y, Watanabe M, Kitawaki T, Shindo T, Hishizawa M, Yamashita K, Ogawa S, Takaori-Kondo A. Next-generation sequencing in two cases of de novo acute basophilic leukaemia. J Cell Mol Med. 25(14): 7095-7099, 2021.
  • Hirabayashi S, Uozumi R, Kondo T, Arai Y, Kawata T, Uchida N, Marumo A, Ikegame K, Fukuda T, Eto T, Tanaka M, Wake A, Kanda J, Kimura T, Tabuchi K, Ichinohe T, Atsuta Y, Yanada M, Yano S. Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT. Cancer Med. 10(13): 4250-4268, 2021.
  • Seo S, Usui Y, Matsuoka T, Atsuta Y, Igarashi A, Fukuda T, Ozawa Y, Katayama Y, Yoshida S, Uchida N, Kondo T, Kako S, Tsukada N, Kato S, Onizuka M, Ichinohe T, Kimura F, Kanda Y, Miyamura K, Kanda J; JSHCT Donor Source Working Group. Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation. Bone Marrow Transplant. 56(10):2410-2422, 2021.
  • Mizuno S, Takami A, Kawamura K, Arai Y, Kondo T, Kawata T, Uchida N, Marumo A, Fukuda T, Tanaka M, Ozawa Y, Yoshida S, Ota S, Takada S, Sawa M, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Yanada M. Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia. Transplant Cell Ther. 27(4): 314.e1-314.e10, 2021.
  • Hamada R, Oshima Y, Sato S, Yoshioka Y, Sato T, Nankaku M, Kondo T, Chen-Yoshikawa TF, Ikeguchi R, Nakajima D, Date H, Matsuda S. Physical function after lung transplantation for late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 29(9): 5447-5454, 2021.
  • Konuma T, Kanda J, Kuwatsuka Y, Yanada M, Kondo T, Hirabayashi S, Kako S, Akahoshi Y, Uchida N, Doki N, Ozawa Y, Tanaka M, Eto T, Sawa M, Yoshioka S, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Kimura F. Differential effect of graft-versus-host disease on survival in acute leukemia according to donor type.Clin Cancer Res . 27(17): 4825-4835, 2021.
  • Harada K, Kimura SI, Fuji S, Najima Y, Yakushijin K, Uchida N, Onizuka M, Ikegame K, Yano S, Shingai N, Matsuoka KI, Onishi Y, Sawa M, Takada S, Kawakita T, Fukuda T, Kanda J, Atsuta Y, Nakasone H. Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 56(9): 2183-2193, 2021.
  • Fujimoto A, Anzai T, Fukuda T, Uchida N, Ohta T, Mori T, Sawa M, Yoshioka S, Miyamoto T, Uchiyama H, Katayama Y, Matsuoka KI, Shiratori S, Nakazawa H, Kanda J, Ichinohe T, Atsuta Y, Fujita N, Kondo E, Suzuki R. Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma. Blood Adv. 5(5): 1412-1424, 2021.
  • Yanada M, Uchida N, Ichinohe T, Fukuda T, Kanda J, Kanda Y, Atsuta Y, Nakasone H. Does one model fit all? Predicting non-relapse mortality after allogeneic hematopoietic cell transplantation.Bone Marrow Transplant . 56(7): 1720-1722, 2021.
  • Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida S, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis .Eur J Haematol. 106(4): 555-562, 2021.
  • Iwaki K, Ueda Y, Mishima M, Narukami S, Shiokawa M, Sawada K, Kanda J, Takahashi K, Seno H. Portal vein thrombosis due to essential thrombocythemia with limited cutaneous systemic sclerosis. Clin J Gastroenterol. 14(1): 293-296, 2021.
  • Kako S, Hayakawa F, Imai K, Tanaka J, Mizuta S, Nishiwaki S, Kanamori H, Mukae J, Ozawa Y, Kondo T, Fukuda T, Ichinohe T, Ota S, Tanaka Y, Murayama T, Kurahashi S, Sakura T, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Atsuta Y. Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.Int J Hematol . 114(5): 608-619, 2021.
  • Konuma T, Kondo T, Masuko M, Shimizu H, Shiratori S, Fukuda T, Kato J, Sawa M, Ozawa Y, Ota S, Uchida N, Kanda Y, Kako S, Fujisawa S, Fukushima K, Ichinohe T, Atsuta Y, Yanada M; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. Bone Marrow Transplant. 56(11): 2779-2787, 2021.
  • Yamashita T, Takamatsu H, Kawamura K, Sunami K, Hagiwara S, Itagaki M, Takahashi T, Kondo T, Ikeda T, Watakabe-Inamoto K, Handa H, Imaizumi Y, Kuroda J, Murakami J, Nakamura Y, Nakazawa H, Ozaki S, Okura M, Takeuchi M, Nagai H, Hanamura I, Nakao S, Iida S. A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival. Br J Haematol. 195(2): 217-229, 2021.
  • Nakamura M, Arai Y, Hirabayashi S, Kondo T, Doki N, Uchida N, Fukuda T, Ozawa Y, Tanaka M, Sawa M, Katayama Y, Kanda Y, Shiratori S, Nakamae H, Yoshioka S, Onizuka M, Ichinohe T, Atsuta Y, Kako S. Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation. Br J Haematol. 194(2): 403-413, 2021.
  • Shimomura Y, Hara M, Hirabayashi S, Kondo T, Mizuno S, Uchida N, Mukae J, Kawakita T, Fukuda T, Kanda Y, Ota S, Ozawa Y, Eto T, Maruyama Y, Tanaka M, Nakano N, Kimura T, Ichinohe T, Atsuta Y, Yanada M. Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. Bone Marrow Transplant. 56(9): 2302-2304, 2021.
  • Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, Sawa M, Ozawa Y, Tanaka M, Uchida N, Nakamae H, Katayama Y, Matsuoka KI, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yano S. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 56(5): 1126-1133, 2021.
  • Yanada M, Konuma T, Yamasaki S, Harada K, Iwasaki M, Kobayashi A, Nishijima A, Tanaka M, Uchida N, Nakamae H, Fukuda T, Onizuka M, Ozawa Y, Sawa M, Katayama Y, Yoshioka S, Kimura T, Ichinohe T, Atsuta Y, Kanda J, Yano S. Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. Transplant Cell Ther. S2666-6367(21)01218-5, 2021.
  • Ino A, Sakanaka K, Inoo H, Ishida Y, Kanda J, Mizowaki T. Definitive radiotherapy for secondary esophageal cancer after allogeneic hematopoietic stem cell transplantation. Int Cancer Conf J. 10(3):201-206, 2021.
  • Watanabe M, Kanda J. [Optimal selection of alternative donors for allogeneic hematopoietic stem cell transplantation]. Rinsho Ketsueki. 62(6): 593-601, 2021.
  • Kurosawa S, Yamaguchi T, Mori A, Matsuura T, Mori T, Tanaka M, Kondo T, Umemoto Y, Goto H, Yoshioka S, Machida S, Sato T, Katayama Y, Kato S, Shono K, Mizuno I, Fujiwara S, Kohno A, Takahashi M, Fukuda T. Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation. J Cancer Surviv. 2021, in press.
  • Fuji S, Hakoda A, Kanda J, Murata M,Terakura S, Inamoto Y, Uchida N, Toya T, Eto T, Nakamae H, Ikegame K,Tanaka M, Kawakita T, Kondo T, Miyamoto T, Fukuda T, Ichinohe T, Kimura T, Atsuta Y, Shintani A, Morishima S. Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 56(12): 2990-2996, 2021.
  • Ito A, Kim SW, Matsuoka KI , Kawakita T , Tanaka T, Inamoto Y, Toubai T, Fujiwara SI, Fukaya M , Kondo T , Sugita J , Nara M , Katsuoka Y, Imai Y, Nakazawa H, Kawashima I, Rika Sakai R, Ishii A , Onizuka M, Takemura T , Terakura S, Iida H , Nakamae M, Higuchi K , Tamura S, Yoshioka S , Togitani K , Kawano N, Suzuki R , Suzumiya J. Izutsu K .Teshima T, Fukuda T. Safety and efficacy of anti‑programmed cell death‑1 monoclonalantibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. Int J Hematol. 112(5): 674-689, 2020
  • Inoue Y, Nakano N, Fuji S, Eto T, Kawakita T, Suehiro Y, Miyamoto T, Sawayama Y, Uchida N, Kondo T, Kanda J, Atsuta Y, Fukuda T, Yoshimitsu M, and Kato k; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma.Bone Marrow Transplant . 56(12): 2964-2974, 2021.